Daniel S Lieber

发表

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Levi Garraway, Uri Tabori, James X. Sun, 2017, Genome Medicine.

The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA

B. Alexander, O. Gjoerup, B. Decker, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Macrocytic anemia and mitochondriopathy resulting from a defect in sideroflexin 4.

V. Mootha, B. Paw, S. Dimauro, 2013, American journal of human genetics.

Next-Generation Sequencing Molecular Diagnosis of Infantile Mitochondrial Disease with Targeted

D. Jaffe, V. Mootha, S. Dimauro, 2012 .

Blood-Based Biomarkers for Cancer Immunotherapy: Tumor Mutational Burden in Blood (bTMB) is Associated with Improved Atezolizumab (atezo) Efficacy in 2L+ NSCLC (POPLAR and OAK)

P. Hegde, T. Mok, D. Gandara, 2017, Pneumologie.

Next generation sequencing with copy number variant detection expands the phenotypic spectrum of HSD 17 B 4-deficiency

V. Mootha, J. Schmahmann, S. Calvo, 2014 .

Next generation sequencing with copy number variant detection expands the phenotypic spectrum of HSD17B4-deficiency

V. Mootha, J. Schmahmann, S. Calvo, 2014, BMC Medical Genetics.

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

Jacob Silterra, David S. Shames, Craig A. Cummings, 2018, Nature Medicine.

Atypical case of Wolfram syndrome revealed through targeted exome sequencing in a patient with suspected mitochondrial disease

V. Mootha, J. Schmahmann, Shangtao Liu, 2012, BMC Medical Genetics.

Global and Local Architecture of the Mammalian microRNA–Transcription Factor Regulatory Network

Yitzhak Pilpel, Daniel Lieber, Moshe Oren, 2007, PLoS Comput. Biol..

Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA

Doron Lipson, Bernard Fendler, Jeffrey P. Gregg, 2018, The Journal of molecular diagnostics : JMD.

Large-Scale Discovery and Characterization of Protein Regulatory Motifs in Eukaryotes

Olivier Elemento, Saeed Tavazoie, Daniel S. Lieber, 2010, PloS one.

Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors

G. Frampton, S. Bailey, O. Gjoerup, 2022, PloS one.

102PAnalytic validation of a next generation sequencing assay to identify tumor mutational burden from blood (bTMB) to support investigation of an anti-PD-L1 agent, atezolizumab, in a first line non-small cell lung cancer trial (BFAST)

D. Lipson, C. Cummings, C. Malboeuf, 2017 .

Molecular Diagnosis of Infantile Mitochondrial Disease with Targeted Next-Generation Sequencing

D. Jaffe, V. Mootha, S. Dimauro, 2012, Science Translational Medicine.

Orthogonal NGS for High Throughput Clinical Diagnostics

Lovelace J. Luquette, Marcia M. Nizzari, E. Mauceli, 2016, Scientific Reports.

Targeted exome sequencing of suspected mitochondrial disorders

V. Mootha, J. Schmahmann, Shangtao Liu, 2013, Neurology.

Computational and Experimental Approaches For Evaluating the Genetic Basis of Mitochondrial Disorders

Daniel S Lieber, 2013 .

Targeted exome sequencing of suspected mitochondrial disorders April

V. Mootha, D. Thorburn, K. Sims, 2013 .

Abstract 5706: A blood-based next-generation sequencing assay to determine tumor mutational burden (bTMB) is associated with benefit to an anti-PD-L1 inhibitor, atezolizumab

D. Lipson, C. Cummings, C. Malboeuf, 2018, Immunology.

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

James X. Sun, L. Garraway, V. Miller, 2017, Genome Medicine.

Next generation sequencing with copy number variant detection expands the phenotypic spectrum of HSD17B4-deficiency

V. Mootha, J. Schmahmann, S. Calvo, 2014, BMC Medical Genetics.